



M. John Chapman, BSc, PhD, DSc, is Director of the Dyslipidemia and Atherosclerosis Research Unit (U.551) of the National Institute of Health and Medical Research (INSERM) at the Pitié-Salpêtrière Hospital, Paris, France, and Research Investigator of the Assistance Publique –Hôpitaux de Paris. He is Past- President of the French Atherosclerosis Society (1998-2005), Past Executive Committee Member of the European Atherosclerosis Society (2000-2004), Executive Committee Member of the International Atherosclerosis Society since 2003, Member of the French National Committee for Research in Cardiovascular Disease since 2002. and Member of the INSERM Commission for Clinical Research since 2005. John is a Founder Member of the European Lipoprotein Club. He is presently Co-Chairman of the International HDL Research Awards Committee.

Following the award of a BSc in Biochemistry from the University of Aberdeen, Scotland, John completed his PhD in Medical Biochemistry at the Courtauld Institute of Biochemistry, Middlesex Hospital Medical School (University of London) as a Research Fellow of the British Heart Foundation. Subsequently , he benefited from postdoctoral training in the laboratories of Drs M.Brown and J.L. Goldstein (Dallas), and of Dr D.M.Small (Boston). In 2002, the University of London Senate awarded John Chapman the Doctor of Science degree for his original career contributions to the field of "Plasma Lipoproteins : Structure, Metabolism and Role in Atherothrombosis".

After initial post-doctoral studies at the Oklahoma Medical Research Foundation, Dr Chapman continued his training under the direction of Dr R.J. Havel at the Cardiovascular Research Institute, University of California Medical Center, San Francisco. On return to Europe, he became a Tenured Research Investigator of INSERM in 1980. For the period 1982-1984, he was an Honorary Visiting Scientist at the Gladstone Foundation for Cardiovascular Disease in San Francisco.

The focal points of his research interests have been the structure, metabolism, and biological activities of atherogenic apo.B-containing particle subspecies (VLDL, LDL) and of anti-atherogenic HDL, the regulation of intravascular lipoprotein metabolism and the role of CETP, the pharmacological modulation of lipoprotein metabolism in atherogenic dyslipidemias, and the role of monocyte – macrophages and foam cells in the inflammatory fragilisation and thrombogenicity of the atherosclerotic plaque.

Dr Chapman is presently Associate European Editor of "*Arteriosclerosis, Thrombosis and Vascular Biology*" and Editorial Board Member of the "*Journal of Lipid Research*", "*Atherosclerosis*", "*Pharmacology and Therapeutics*" and "*Future Lipidology*". Dr Chapman acts as an Expert to several international research organisations, including the Wellcome Trust, British Heart Foundation, NHMRC (Australia), Dutch Heart Foundation, Austrian FWF, The Human Science Frontier Programme and the National Science Foundation (USA).

John has presented plenary conferences in more than 40 countries in Europe, North and South America, the Middle East, Asia, South East Asia and Australia, and has authored more than 350 original publications and book chapters in the course of his career. Indeed, his review on "Animal Lipoproteins: Structure and Comparative Aspects" is a citation classic. John recently became an Associate member of a TransAtlantic Research Network of Excellence funded by the Fondation Leducq entitled "Immune regulation of Atherosclerosis", under the leadership of Dr. J.L.Witztum.